Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP19 | O94966 | 4/20 | 0.35 |
| ▸ | PSMB1 | P20618 | 3/20 | 0.34 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.34 |
| ▸ | DDR1 | Q08345 | 3/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
| ▸ | FLT3 | P36888 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.30 |
| ▸ | HTR3A | P46098 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23994584 | 0.83 | HTR3A (0.35) | HTR3A | |
| SCHEMBL25004510 | 0.74 | CHEK1 (0.33) | CHEK1 | |
| SCHEMBL30181718 | 0.72 | MEN1 (0.31) | MEN1KMT2A | |
| SCHEMBL23993848 | 0.72 | MEN1 (0.31) | MEN1KMT2A | |
| SCHEMBL25005534 | 0.72 | HTR3A (0.36) | HTR3A | |
| SCHEMBL23995229 | 0.71 | PDE10A (0.32) | PDE10A | |
| SCHEMBL30224160 | 0.71 | PSMB1 (0.49) | USP19PSMB1PSMB5DDR1HDAC3 | |
| SCHEMBL2950988 | 0.71 | PSMB1 (0.49) | USP19PSMB1PSMB5DDR1HDAC3 | |
| SCHEMBL2960107 | 0.71 | MEN1 (0.37) | USP19PSMB1PSMB5DDR1HDAC3 | |
| SCHEMBL2952038 | 0.70 | PSMB1 (0.35) | USP19PSMB1PSMB5DDR1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230039553-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
| WO-2021222522-A1 | CD73 INHIBITING 2,4-DIOXOPYRIMIDINE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230039553-A1 | CD73 COMPOUNDS | ENTPD5, ENTPD1, NT5E | USP19 4662/4885PSMB1 4783/4885PSMB5 4616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.